Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 53:2019-2027, doi:10.1016/j.jacc.2008.12.073
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Related Cardiosource Journal Scan
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Doyle, B. J.
Right arrow Articles by Holmes, D. R.
PubMed
Right arrow Articles by Doyle, B. J.
Right arrow Articles by Holmes, D. R., Jr
Related Collections
Right arrowRelated Article

STATE-OF-THE-ART PAPER

Bleeding, Blood Transfusion, and Increased Mortality After Percutaneous Coronary Intervention

Implications for Contemporary Practice

Brendan J. Doyle, MB, BCh*, Charanjit S. Rihal, MD, MBA*, Dennis A. Gastineau, MD{dagger} and David R. Holmes, Jr, MD{dagger},*

* Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota
{dagger} Division of Hematology and Transfusion Medicine, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota

Manuscript received June 27, 2008; revised manuscript received December 15, 2008, accepted December 15, 2008.

* Reprint requests and corresponding: Dr. David R. Holmes, Jr., Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905 (Email: holmes.david{at}mayo.edu).

Advances in percutaneous coronary intervention (PCI) during the past decade have led to more widespread use of these procedures in older and sicker patients. Refinement of periprocedural antithrombotic therapy has played a particularly important role in reducing ischemic complications to very low levels in routine practice. Although the use of more powerful antiplatelet agents has been associated with increased risk of bleeding (especially among the elderly and patients with serious comorbidities), such complications have traditionally been viewed as benign in nature. Recent studies, however, have identified major bleeding after PCI as an important predictor of increased mortality. Whether this relationship between bleeding and risk of death is cause-and-effect, or merely an association based on shared risk factors, remains unclear. In this review, we examine the basis for a possible causal link between post-PCI bleeding and subsequent mortality. Possible mechanisms underpinning such a link are discussed, including a potential adverse role for blood transfusion in this setting. A framework for further clinical evaluation of this issue is presented.

Key Words: bleeding • blood transfusion • percutaneous coronary intervention

Abbreviations and Acronyms
  MI = myocardial infarction
  NO = nitric oxide
  PAI = plasminogen activator inhibitor
  PCI = percutaneous coronary intervention
  RBC = red blood cell(s)
  TRIM = transfusion-related immunomodulation


Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A29. [Full Text] [PDF]





 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement